A real-world study of health care resource utilization (HCRU) in patients with myasthenia gravis on second-line therapy identified the factors that led to increased financial burdens. A recent study ...
Comorbidities and older age increase the risk of severe COVID-19 in MG patients, but not susceptibility to infection. MG treatments, including corticosteroids and immunosuppressants, do not heighten ...
Myasthenia gravis is a chronic autoimmune disorder that inhibits communication between nerve cells and muscles, causing muscle weakness. It has no cure, but several treatment options can help improve ...
Five therapies are currently approved by the FDA for treating the symptoms of myasthenia gravis, allowing partial to complete remission. Research suggests that five new therapies may become available ...
Former tennis star Monica Seles recently revealed she is living with the rare disease myasthenia gravis, which affects 12 in 100,000 people globally. Seles explained her first symptoms appeared ...
The first study to use an RNA-based chimeric antigen receptor T-cell (rCAR-T) therapy in autoimmune disease showed people with generalized myasthenia gravis tolerated the treatment well and ...
The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen's UPLIZNA(R) (inebilizumab-cdon) for the treatment of generalized myasthenia gravis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback